Final Version published in @BloodJournal, check it out! ashpublications.org/blood/article-…

Ladies and gentlemen, I present you with the worst take you’ll see all year.

RR #DLBCL #Lymphoma & secondary #CNS Involvement #CART #celltherapy has seen more #realworld data of late. Latest is the🇩🇪 #registry LONG-TERM #data from Nico Gagelmann & team 👍reassuring - outcomes comparable with those without, & no ⬆️in #ICANS or #CRS. ashpublications.org/bloodadvances/…

ASH is strongly urging American Board of Internal Medicine (ABIM) to take immediate action to establish a new MOC program that does not involve high-stakes assessments to better serve our members. Read the full text of ASH’s letter: loom.ly/xXS6uqQ ABMS

Ouch. Bendamustine is bad news for CAR T-cells in FL too - figure below from just-published ZUMA-5 data in @BloodJournal as per Gloria Iacoboni I wonder whether this effect is overcome with BsAbs given repeat stimulation of the T-cells ashpublications.org/blood/article/… Ash Alizadeh, MD/PhD 🇺🇸

#ASH23 Michael Cook from Penn Medicine discusses impact of bridging therapy (BT) prior to axi-cel treatment in pts with LBCL. N=1307; ORR with and without bridging therapy=70% vs 79%; CR= 51% vs 64% respectively. Grade ≥3 CRS and ICANS in BT vs no BT=12% and 30% vs 10% and

Bridging Therapy Prior to Axi-Cel Produces Favorable Real-World Outcomes in R/R LBCL @michael_r_cook4 Penn Medicine @ASH_Hematology #ASH23 #lymsm onclive.com/view/addition-…

Thanks to @michael_r_cook4, of Penn Medicine, for joining us during ASH to speak about the impact of bridging therapy prior to axi-cel in R/R LBCL! Head to our site to see how day 1 of the meeting wraps! #ASH23 #lymsm onclive.com/conference/ash

#ASH23 continues to amaze with surprise meetups on hallways and sidewalks!! So nice to see you both Dr. Erika Haydu MassGeneral News and Michael Cook Penn Medicine Good old ASCO AACR #Vail2021 company!! @VUMCHemOnc

WATCH: Michael R. Cook, MD, discusses real-world data associated with the utilization of bridging therapy prior to treatment with axi-cel in patients with R/R LBCL. Michael Cook Penn Medicine ASH #ASH23 #lymsm onclive.com/view/dr-cook-o…

Exciting news! We've established a groundbreaking collaboration with the University of Pennsylvania's (UPenn) School of Clinical Medicine as part of our Centres of Excellence (CoE) programme. ​ We can't wait to see how this collaboration will take us closer to a cure for FL!

If there’s not a graphic, depicting the three Steelers QBs as the ghosts of Christmas past, present and future, I’m going to be v disappointed.

And the total for THON 2024, Treasure Every Adventure, is $16,955,683.63

Comparison of CAR T-cell vs. bispecific Ab as 3rd(+) line DLBCL Rx: A Meta-analysis 16 studies: 1,347 pts in pooled analysis •CAR-T: superior efficacy: ⬆️CR & pooled 1yr PFS cf bispecifics but •CAR-T exhibits ⬆️ incidence ≥G3 AEs cf bispecifics ashpublications.org/blood/article/…

CD19-specific CAR T cells engineered to secrete interleukin-18 were used to treat patients with lymphoma after previous CAR T failure, with a complete or partial response of 81% and a complete response of 52%. Full trial results: nej.md/4jSiXkX

Just out at Journal of Clinical Oncology: COALITION study comparing glofitamab + PolaR-CHP vs glofit-R-CHOP in frontline large B cell lymphoma - very exciting n=80 ORR 100% CRR 98% 21 month PFS 86%, OS 92% ascopubs.org/doi/10.1200/JC… Congrats Michael Dickinson Adrian Minson ! #lymsm #18ICML

Prolonged MTR for induction and consolidation is a safe alternative treatment strategy for the management of PCNSL. ow.ly/tkO350WJ6fw #lymphoidneoplasia #lymphoma